

Board Report

2 June 2017

Paul Mitchell

Olivia Newton-John Cancer and Wellness Centre,
Austin Health & University of Melbourne
Chairman, TACT

paul.mitchell@austin.org.au

+61 432 004 528



Background to establishing TACT

- 2013-2014
 - Meetings of 25+ groups involved in thoracic oncology research at key conferences to discuss the need for a global effort
- ASCO 2014
 - Agreement to move ahead, Steering Committee established led by ALTG (legal entity Lung Foundation Australia)
- World Lung Cancer Conference 2015
 - TACT formally established



Why TACT? -the status of lung cancer research

- Lung cancer is both the most common cancer and the greatest cause of cancer death globally
- Outcomes remain poor with 5-year relative survival of only 14% in countries with the best outcomes
- The best outcomes for early stage patients are mostly achieved with multi-modality therapy
- For patients with advanced incurable disease, there have been major recent advances in EGFR and ALK mutated cancer.
- Many more targeted therapies as well as immunotherapies are showing impressive results.



Why TACT? - A global effort in clinical research will address significant challenges

- Trials requiring very large numbers of patients
 - eg Adjuvant trials post-surgery
- Multimodality therapy
 - eg Stage III NSCLC
- Rare molecular subgroups
 - eg Adjuvant TKI following surgery for ALK+ NSCLC
- Rare thoracic malignancies
 - Thymic tumours, mesothelioma



Why TACT? - A global effort in clinical research will address significant challenges

- Completion of thoracic malignancy trials in a timely way – especially for rare diseases
- Provides an international framework for clinical research and research planning – rather than trial specific *ad hoc* consortia




Who is doing the research?

- Advances in treatment are based on basic science and on drug development
- Pharmaceutical company sponsored research
- Scientific co-operative group research
 - Collaborations of scientists and clinician researchers
 - Often better placed to do complex research
 - Focused on science



Lung cancer and oncology groups involved to date



TACT Board

Paul Mitchell (Chair)

Glen Goss

Rebecca Heist

Karen Kelly

Bartomeu Massuti

Tony Mok

Marianne Nicolson

Mary O'Brien

Ken O'Byrne

Nick Pavlakis

Suresh Ramalingam

Rolf Stahel

Virginie Westeel

ALTG – Australia/NZ

NCIC-CTG – Canada

Alliance – USA

SWOG – USA

GECP/SLCG – Spain

Asia representative

NCRI-CSG – UK

EORTC – Europe

ALTG – Australia/NZ; ETOP

ALTG – Australia/NZ

ECOG – USA

ETOP; SAKK – Europe/Switzerland

IFCT – France



Mission

- TACT is an international non-profit umbrella organisation for academic research groups from around the world, dedicated to facilitating thoracic oncology research
 - An organisation which brings together national and trans-national cancer research groups
 - An academic co-operative group focused on thoracic malignancy



Aims

- Facilitate and promote international research collaboration in thoracic cancer
- Provide a platform to conduct clinical trials requiring multiple trials groups
- Combine resources and expertise to conduct research more efficiently and reduce duplication of effort
- Allow trials to recruit more quickly
- Establish clinical and translational research priorities



Members

Europe

- APRIC (Italy)
- CECOG (Central European Clinical Oncology Group)
- ETOP (European Thoracic Oncology Platform)
- Cancer Trials Ireland (previously ICORG)
- IFCT (France)
- GECP (Spain)
- NCRI Lung CSG (National Cancer Research Institute Clinical Studies Group – UK)

North America

- Alliance
- ECOG (Eastern Co-operative Oncology Group)
- SWOG (South-West Oncology Group)
- CCTG (Canadian Cancer Trials Group) - pending

Asia-Pacific

- ALTG (Australasian Lung Cancer Trials Group)
- JCOG (Japan Clinical Oncology Group)
- TROG (Trans-Tasman Radiation Oncology Group)

Observers and Partners

- Observers
 - BTOG (British Thoracic Oncology Group)
 - ITONF (International Thoracic Oncology Nurses Forum)
- IASLC – special partner
- Industry Partners



Bristol-Myers Squibb




Observers and Partners

- Also present today
 - Potential Members
 - Groups / individuals with a special interest in lung cancer
 - Pharmaceutical Industry



Activities to date

- Meetings with pharmaceutical industry:
 - Immunotherapy, adjuvant treatment, EGFR-mutated, rare mutations
 - AstraZeneca, Celgene, BI, BMS
 - Roche, MSD, Incyte, Ignyta, Lilly, Merck Serono, Novartis, Pfizer, AbbVie



Activities to date


- Meetings with other international groups
 - GCIG (joint use of venue at ASCO)
 - BIG
- Meetings with IASLC
- Meetings with NCI-CTEP
- Issues which impact on the conduct of clinical trials across national boundaries - HARMONISATION



Activities to date

- Trials - mechanisms
 - Groups can bring trials to TACT
 - TACT Executive / Board develop trials with industry
- STIMULI Trial
 - An ETOP (and IFCT) existing study
 - Limited Stage - Small Cell Lung Cancer
 - Consolidation immunotherapy
- Potential rare mutations in NSCLC trial





- Home icon
- About
- Collaborate
- Meetings
- Resources
- ConTACT

Thoracic Alliance for Cancer Trials

TACT is an international non-profit collaboration of groups dedicated to thoracic oncology clinical research. Our worldwide network helps researchers navigate an increasingly complex landscape as understanding of lung cancer and new treatment approaches evolve.

[LEARN MORE](#)



Welcome

Enquiries

Welcome to the website of TACT, the Thoracic Alliance for Cancer Trials. TACT is a unique opportunity to improve outcomes for patients with thoracic malignancy by facilitating clinical research through a truly global network, harmonisation of governance and operations and fostering a genuine collaboration among groups and with external partners. TACT was established in September 2015 at the 16th World Conference on Lung Cancer in Denver, Colorado as an international non-profit umbrella organisation for worldwide academic groups who are dedicated to thoracic oncology research. With our global reach, TACT is ideally positioned to navigate the increasingly complex landscape of lung cancer diagnosis and novel treatment approaches by enabling lung cancer researchers worldwide to work together on joint projects and clinical trials.

Paul Mitchell, Board Chair

TACT Development Officer
c/o Lung Foundation Australia

PO Box 1949
Milton QLD 4064
Australia

T: +61 (0) 7 3251 3600
M: +61 (0) 481 394 982
F: +61 (0) 7 3368 3564
E: enquiries@tactlung.com